Dishman Carbogen Amcis’ subsidiary -- Carbogen Amcis AG has entered into strategic partnership to offer a fully integrated Antibody-Drug Conjugate (ADC) development and manufacturing solution with Celonic Group. The alliance combines Celonic’s advanced biologics capabilities with CARBOGEN AMCIS’s expertise in payload synthesis, conjugation, and sterile fill-finish, creating a seamless, end-to-end platform for ADC innovators.
This partnership addresses a critical need in the biopharmaceutical sector, where the complexity of ADC development often necessitates collaboration between multiple vendors. By combining their strengths, Celonic and CARBOGEN AMCIS aim to streamline the supply chain, speed up timelines, and support clients from early-stage development through to commercial launch.
Dishman Carbogen Amcis (DCAL), incorporated in 1983, started out as a manufacturer of quaternary ammonium and phosphate compounds. Currently, the company is a fully integrated CRAMS player working with global pharmaceutical innovators.
